Isatuximab

IKEMA: isatuximab, carfilzomib and dexamethasone in RRMM 3:46
IKEMA: isatuximab, carfilzomib and dexamethasone in RRMM
Roman Hajek • 10 Jun 2021
The antibody treatment landscape in myeloma 1:28
The antibody treatment landscape in myeloma
Sagar Lonial • 9 Jun 2021
CD38 and SLAMF7 targeting for multiple myeloma 2:49
CD38 and SLAMF7 targeting for multiple myeloma
Enrique Ocio • 26 May 2021
Updates on belantamab mafodotin for myeloma 2:38
Updates on belantamab mafodotin for myeloma
Claudio Cerchione • 25 May 2021
New approaches to the treatment of elderly myeloma 5:07
New approaches to the treatment of elderly myeloma
Meral Beksac • 10 May 2021
A new era of treatment for multiple myeloma 2:30
A new era of treatment for multiple myeloma
Mohamad Mohty • 16 Apr 2021
IKEMA: isatuximab addition to Kd improves depth of response in myeloma 2:34
IKEMA: isatuximab addition to Kd improves depth of response in myeloma
Thomas Martin • 9 Mar 2021
HRQoL and frail patients with R/R multiple myeloma 2:43
HRQoL and frail patients with R/R multiple myeloma
Maria-Victoria Mateos • 10 Mar 2021
Monoclonal antibodies for myeloma relapsed after ASCT 4:24
Monoclonal antibodies for myeloma relapsed after ASCT
Mohamad Mohty • 24 Feb 2021
Monoclonal antibodies for lenalidomide-refractory multiple myeloma 1:35
Monoclonal antibodies for lenalidomide-refractory multiple myeloma
Enrique Ocio • 19 Feb 2021
Mass spectrometry and response monitoring in multiple myeloma 4:22
Mass spectrometry and response monitoring in multiple myeloma
David Murray • 23 Feb 2021
IKEMA subgroup analysis: Isa + Kd in patients who previously underwent transplantation 3:51
IKEMA subgroup analysis: Isa + Kd in patients who previously underwent transplantation
Thomas Martin • 10 Feb 2021
What does the future of amyloidosis treatment look like? 2:09
What does the future of amyloidosis treatment look like?
Efstathios Kastritis • 11 Dec 2020
SWOG S1702: isatuximab for AL amyloidosis 1:44
SWOG S1702: isatuximab for AL amyloidosis
Vaishali Sanchorawala • 7 Dec 2020
IKEMA: isatuximab + Kd improves response and PFS in R/R myeloma 2:40
IKEMA: isatuximab + Kd improves response and PFS in R/R myeloma
Thomas Martin • 17 Dec 2020
MRD-negativity rates in the IKEMA trial of isa plus kD in R/R myeloma 2:32
MRD-negativity rates in the IKEMA trial of isa plus kD in R/R myeloma
Philippe Moreau • 4 Dec 2020
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals